Home » DUPONT EXPECTS PROFIT DROP AS DRUG GOES OFF PATENT IN 2010
DUPONT EXPECTS PROFIT DROP AS DRUG GOES OFF PATENT IN 2010
DuPont Co. will see a rapid drop in profits from hypertension drug Cozaar/Hyzaar
starting in 2010, Chief Executive Officer Charles O. Holliday Jr. told analysts
today. The drug, which contributed more than $675 million to DuPont's earnings
last year, will go off patent in 2010, Holliday told analysts at a conference
in Miami Beach, Fla., which aired on the company's Web site.
DelawareOnline
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May